We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LYV:NYSELive Nation Entertainment, Inc. Analysis

Data as of 2026-03-10 - not real-time

$165.53

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Live Nation’s price is trading comfortably above both its 20‑day and 50‑day moving averages, and the MACD histogram remains in bullish territory, suggesting short‑term momentum is intact. The RSI sits in the upper‑mid range, indicating strength without clear overbought pressure, while volume has been stable, supporting the price advance. However, the stock’s forward price‑to‑earnings multiple towers far above the industry average and the DCF‑derived fair value still trails the current market price, flagging a potentially stretched valuation. Volatility over the past month is elevated and beta is modest, pointing to a stock that can swing sharply but is less correlated with broader market moves.
On the fundamental side, revenue is growing at double‑digit rates and the company continues to benefit from robust concert demand and expanding sponsorship bookings. Margins remain thin and the firm carries a high debt load relative to equity, with no dividend to offset the valuation concerns. The most material catalyst this week is the DOJ settlement, which eases immediate antitrust pressure but does not eliminate the underlying regulatory risk. Investors should weigh the bullish technical setup and growth narrative against the lofty valuation, heavy leverage, and lingering legal exposure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent DOJ settlement reduces immediate legal uncertainty
  • Bullish technical indicators support current price levels
  • Valuation remains stretched relative to earnings outlook

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained revenue growth and strong concert demand
  • Potential for improved margins as sponsorships expand
  • Resolution of antitrust issues could unlock upside

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Long‑term structural shift toward live experiences
  • High leverage and lack of dividend limit downside protection
  • Valuation premium may persist without clear earnings acceleration

Key Metrics & Analysis

Financial Health

Revenue Growth11.10%
Profit Margin1.97%
P/E Ratio73.0
ROE36.70%
ROA3.89%
Debt/Equity572.03
P/B Ratio142.9
Op. Cash Flow$1.4B
Free Cash Flow$1.1B
Industry P/E18.2

Technical Analysis

TrendBullish
RSI63.5
Support$147.72
Resistance$168.54
MA 20$158.42
MA 50$150.12
MA 200$149.90
MACDBullish
VolumeStable
Fear & Greed Index76.91

Valuation

Fair Value$90.68
Target Price$182.59
Upside/Downside10.31%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.89
Volatility34.09%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.